在PK的高峰-药物动力学的介绍

H. Twitchett, P. Grimsey
{"title":"在PK的高峰-药物动力学的介绍","authors":"H. Twitchett, P. Grimsey","doi":"10.1179/1757092112Z.0000000007","DOIUrl":null,"url":null,"abstract":"The aim of this paper is to give a high level introduction into pharmacokinetic (PK) data and analysis for programmers new to PK, or who require a refresher. Key theoretical concepts will be covered, such as: absorption, distribution, metabolism, and elimination (ADME), derived PK parameters, including area under the curve (AUC), Cmax (maximum concentration observed), tmax (time of maximum concentration observed), and t1/2 (half-life), and steady state. The data flow from CRF to tables, figures and listings (TFLs) will also be covered. We shall also briefly discuss the use of PK in the drug development process including types of clinical studies, e.g. single ascending dose (SAD), multiple ascending dose (MAD), bioavailability, mass balance, food effect, and drug–drug interaction (DDI) studies, and how this relates to the PK of the drug.","PeriodicalId":253012,"journal":{"name":"Pharmaceutical Programming","volume":"32 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"A peak at PK — an introduction to pharmacokinetics\",\"authors\":\"H. Twitchett, P. Grimsey\",\"doi\":\"10.1179/1757092112Z.0000000007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of this paper is to give a high level introduction into pharmacokinetic (PK) data and analysis for programmers new to PK, or who require a refresher. Key theoretical concepts will be covered, such as: absorption, distribution, metabolism, and elimination (ADME), derived PK parameters, including area under the curve (AUC), Cmax (maximum concentration observed), tmax (time of maximum concentration observed), and t1/2 (half-life), and steady state. The data flow from CRF to tables, figures and listings (TFLs) will also be covered. We shall also briefly discuss the use of PK in the drug development process including types of clinical studies, e.g. single ascending dose (SAD), multiple ascending dose (MAD), bioavailability, mass balance, food effect, and drug–drug interaction (DDI) studies, and how this relates to the PK of the drug.\",\"PeriodicalId\":253012,\"journal\":{\"name\":\"Pharmaceutical Programming\",\"volume\":\"32 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical Programming\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1179/1757092112Z.0000000007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Programming","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1179/1757092112Z.0000000007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

本文的目的是给药代动力学(PK)的数据和分析的高层次介绍给程序员新的PK,或谁需要复习。关键的理论概念将包括:吸收,分布,代谢和消除(ADME),衍生的PK参数,包括曲线下面积(AUC), Cmax(观察到的最大浓度),tmax(观察到的最大浓度时间)和t1/2(半衰期),以及稳态。还将介绍从CRF到表、图和清单(tfl)的数据流。我们还将简要讨论药物开发过程中PK的使用,包括临床研究类型,例如单次上升剂量(SAD),多次上升剂量(MAD),生物利用度,质量平衡,食物效应和药物-药物相互作用(DDI)研究,以及这些与药物PK的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A peak at PK — an introduction to pharmacokinetics
The aim of this paper is to give a high level introduction into pharmacokinetic (PK) data and analysis for programmers new to PK, or who require a refresher. Key theoretical concepts will be covered, such as: absorption, distribution, metabolism, and elimination (ADME), derived PK parameters, including area under the curve (AUC), Cmax (maximum concentration observed), tmax (time of maximum concentration observed), and t1/2 (half-life), and steady state. The data flow from CRF to tables, figures and listings (TFLs) will also be covered. We shall also briefly discuss the use of PK in the drug development process including types of clinical studies, e.g. single ascending dose (SAD), multiple ascending dose (MAD), bioavailability, mass balance, food effect, and drug–drug interaction (DDI) studies, and how this relates to the PK of the drug.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信